ATE124936T1 - 5-benzyl barbitursäurederivate. - Google Patents

5-benzyl barbitursäurederivate.

Info

Publication number
ATE124936T1
ATE124936T1 AT91908585T AT91908585T ATE124936T1 AT E124936 T1 ATE124936 T1 AT E124936T1 AT 91908585 T AT91908585 T AT 91908585T AT 91908585 T AT91908585 T AT 91908585T AT E124936 T1 ATE124936 T1 AT E124936T1
Authority
AT
Austria
Prior art keywords
acid derivatives
barbituric acid
benzyl
toxicity
compounds
Prior art date
Application number
AT91908585T
Other languages
English (en)
Inventor
Fardos N M Naguib
Kouni Mahmoud H El
Raymond P Panzica
Sungman Cha
Original Assignee
Univ Brown Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Brown Res Found filed Critical Univ Brown Res Found
Application granted granted Critical
Publication of ATE124936T1 publication Critical patent/ATE124936T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT91908585T 1990-04-12 1991-04-12 5-benzyl barbitursäurederivate. ATE124936T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/508,363 US5141943A (en) 1990-04-12 1990-04-12 5-benzyl barbiturate derivatives

Publications (1)

Publication Number Publication Date
ATE124936T1 true ATE124936T1 (de) 1995-07-15

Family

ID=24022452

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91908585T ATE124936T1 (de) 1990-04-12 1991-04-12 5-benzyl barbitursäurederivate.

Country Status (10)

Country Link
US (1) US5141943A (de)
EP (1) EP0526537B1 (de)
JP (1) JP3001972B2 (de)
AT (1) ATE124936T1 (de)
AU (1) AU7776891A (de)
CA (1) CA2080343C (de)
DE (1) DE69111232T2 (de)
DK (1) DK0526537T3 (de)
ES (1) ES2077850T3 (de)
WO (1) WO1991016315A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US7776838B1 (en) 1987-10-28 2010-08-17 Wellstat Therapeutics Corporation Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US5691320A (en) 1987-10-28 1997-11-25 Pro-Neuron, Inc. Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9214720D0 (en) * 1992-07-10 1992-08-19 Wellcome Found Enzyme inhibitors
CA2150940C (en) * 1992-12-08 2007-08-21 Reid Warren Von Borstel Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
AU6087894A (en) * 1993-01-14 1994-08-15 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
US5567689A (en) * 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5476855A (en) * 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
EP0748316B1 (de) * 1994-02-28 2002-05-08 Sunkyong Industries Co., Ltd. Pyrimidin-acyclonukleosid-derivate
JP4408450B2 (ja) * 1994-07-01 2010-02-03 ウェルスタット セラピューティクス コーポレイション 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体
US7198190B2 (en) * 1997-03-12 2007-04-03 Dodge Juhan Identification device having reusable transponder
JPH11279157A (ja) * 1998-03-27 1999-10-12 Hoechst Marion Roussel Kk バルビツール酸誘導体およびそれらからなる骨・軟骨疾患予防・治療薬
EP1083172A4 (de) * 1998-05-26 2001-10-10 Rimma Iliinichna Ashkinazi N-substituierte derivate von 5-oxyaminobarbitursaüre
DK1140104T3 (da) 1998-07-31 2008-01-21 Massachusetts Inst Technology Behandling af Alzheimer's sygdom ved forögelse af cytidinniveauer in vivo
US8143234B2 (en) * 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US8518882B2 (en) 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US20060069061A1 (en) * 1998-07-31 2006-03-30 Dick Wurtman Compositions containing uridine and choline, and methods utilizing same
US8314064B2 (en) * 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
GB0013655D0 (en) * 2000-06-05 2000-07-26 Prolifix Ltd Therapeutic compounds
DE10110355A1 (de) * 2001-03-03 2002-09-12 Ulrich Walker Bekämpfung von Nebenwirkungen
BRPI0817387A2 (pt) * 2007-11-02 2015-09-08 Massachusetts Inst Technology métodos de conformidade de suplementação dietária de uridina e uso dos mesmos
CN102014919B (zh) 2008-03-03 2015-02-25 托斯克公司 减少毒性的甲氨蝶呤佐剂及其使用方法
RU2581467C1 (ru) * 2015-04-06 2016-04-20 Федеральное государственное бюджетное учреждение науки "Институт токсикологии Федерального медико-биологического агентства" Антидот окиси углерода
DE102016011954A1 (de) * 2016-10-07 2018-04-12 Merck Patent Gmbh Barbitursäurederivate als Selbstbräunungssubstanzen
CN111936498B (zh) 2018-03-26 2024-04-16 诺华股份有限公司 N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
CN114521196A (zh) * 2019-09-16 2022-05-20 诺华股份有限公司 双官能团降解剂及其使用方法
WO2024200612A1 (en) * 2023-03-30 2024-10-03 Université de Lausanne Inhibitors of uridine catabolism and/or transport for therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282921A (en) * 1964-06-04 1966-11-01 Syntex Corp Halo-deoxynucleosides and processes for the preparation thereof
US3464990A (en) * 1967-02-27 1969-09-02 Hoffmann La Roche Barbituric acid derivatives substituted in the five position
US3755295A (en) * 1969-10-24 1973-08-28 Syntex Corp 1-(2-amino-2-deoxy-{62 -d-ribofuranosyl) pyrimidines and derivatives thereof
US3775397A (en) * 1969-11-12 1973-11-27 Akad Wissenschaften Ddr Novel cytostatic 2',3'-dideoxy-3'-fluoropyrimidine-nucleosides
US3687931A (en) * 1970-03-19 1972-08-29 Syntex Corp Halogenated purine and pyrimidine nucleosides and process therefor
US3817982A (en) * 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
DE2627076A1 (de) * 1976-06-16 1977-12-29 Max Planck Gesellschaft Mittel zur inhibierung des zellwachstums
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
US4093715A (en) * 1977-04-28 1978-06-06 Research Corporation 5-Iodo-5'-amino-2',5'-dideoxycytidine and the pharmaceutically acceptable salts thereof
US4128639A (en) * 1977-12-14 1978-12-05 Research Corporation Nitrosourea analogs of thymidine
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
US4230698A (en) * 1978-05-12 1980-10-28 Research Corporation 2-Substituted arabinofuranosyl nucleosides and nucleotides
US4604382A (en) * 1983-01-17 1986-08-05 Research Corporation 3'-amino-2',3'-dideoxycytidine and the pharmacologically acceptable salts thereof
US4681933A (en) * 1986-05-01 1987-07-21 University Of Georgia Research Foundation, Inc. 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents

Also Published As

Publication number Publication date
CA2080343A1 (en) 1991-10-13
CA2080343C (en) 2001-10-23
DE69111232D1 (de) 1995-08-17
EP0526537B1 (de) 1995-07-12
DK0526537T3 (da) 1995-10-02
DE69111232T2 (de) 1995-12-21
AU7776891A (en) 1991-11-11
US5141943A (en) 1992-08-25
JPH05506240A (ja) 1993-09-16
JP3001972B2 (ja) 2000-01-24
WO1991016315A1 (en) 1991-10-31
EP0526537A1 (de) 1993-02-10
ES2077850T3 (es) 1995-12-01

Similar Documents

Publication Publication Date Title
DE69111232D1 (de) 5-benzyl barbitursäurederivate.
DK0545966T3 (da) Phospholipidderivater af nucleosider, deres fremstilling samt deres anvendelse som anti-virale lægemidler
DK0465297T3 (da) 9-Purinylphosphonsyre-derivater
MX9303711A (es) Nucleosidos de pirimida sustituida que tienen actividad anti-tumoral y anti-viral y composicion farmaceutica que los contiene.
ATE225341T1 (de) In 6-position durch thio substituierte paclitaxele
DE60101223D1 (de) Antivirale pyrimidin nucleoside derivate
PT100199A (pt) Combinacao antiviral de nucleosidos e processo para a sua preparacao
BR9914221B1 (pt) Derivados de glicopeptídeos e composições farmacêuticas contendo os mesmos
PT1066269E (pt) Derivados de 1,3,5-triazina trissubstrituidos para o tratamento de infeccoes por hiv
BR0113146A (pt) Derivados de prolina e uso destes como drogas
ATE137242T1 (de) Kovalente-ther lipidnukleosid-konjugate
PT911333E (pt) Derivados de pirazolo¬4,3-d|pirimidina e composicoes farmaceuticas que os contenham
ES2074719T3 (es) Derivados de nucleosido de pirimidina.
YU13396A (sh) N-(3-benzofuranil) urea derivati, postupci za njihovo dobijanje, kompozicije koje ih sadrže i njihova upotreba u lekovima
NL300247I1 (nl) 2-Halogeen-9-(2-desoxy-2-fluor-bêta-D-arabinofuranosyl)-adeninenucleosiderivaten.
ATE205850T1 (de) Behandlung der toxischen wirkung von chemotherapeutischen und antiviralen wirkstoffen mit acylierten pyrimidinnukleosiden
FI942188A7 (fi) Triatsiinijohdannaisia kasvaintenvastaisen aktiivisuuden tehostamiseks i
BR0207102A (pt) Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença
PT1102594E (pt) Utilizacao de cloreto de sodio para reduzir a toxicidade gastrointestinal de derivados de camptotecina
ES2062724T3 (es) Utilizacion de derivados de la triazina y de la pirimidina para la obtencion de medicamentos que combaten la resistencia a los agentes anticancerosos y antimalaricos.
EP0650723A3 (de) Neue pharmazeutische Verwendungen von Forskolin-Derivaten.
IT8821570A0 (it) Impiego di derivati adenosinici per la preparazione di composizioni farmaceutiche aventi attivita' immunostimolante.
NO913659D0 (no) Hemming av hiv ved anvendelse av synergistiske kombinasjoner av nukleosidderivater.
FI912513L (fi) Syntes av nukleotid- och nukleosidderivat.
OA08742A (fr) Dérivés de pyrimidine.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee